Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.

Dobashi Y, Tsubochi H, Minegishi K, Kitagawa M, Otani S, Ooi A.

Hum Pathol. 2017 Aug;66:67-78. doi: 10.1016/j.humpath.2017.05.022. Epub 2017 Jun 7.

PMID:
28601655
2.

Regulation of transcriptional activators by DNA-binding domain ubiquitination.

Landré V, Revi B, Mir MG, Verma C, Hupp TR, Gilbert N, Ball KL.

Cell Death Differ. 2017 May;24(5):903-916. doi: 10.1038/cdd.2017.42. Epub 2017 Mar 31.

3.

miR-31 mutants reveal continuous glial homeostasis in the adult Drosophila brain.

Foo LC, Song S, Cohen SM.

EMBO J. 2017 May 2;36(9):1215-1226. doi: 10.15252/embj.201695861. Epub 2017 Mar 20.

4.

High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.

Bao Y, Wu X, Yuan D, Shi W, Shi J.

Cell Mol Neurobiol. 2017 Nov;37(8):1501-1509. doi: 10.1007/s10571-017-0481-5. Epub 2017 Mar 3.

PMID:
28258514
5.

E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.

Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA.

Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.

6.

p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.

Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfeld R, von Brunn A.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5192-201. doi: 10.1073/pnas.1603435113. Epub 2016 Aug 12.

7.

Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.

Yang S, Chen Y, Sun F, Ni Q, Wang H, Huang Y, Zhang C, Liu K, Wang S, Qiu J, Xu Z, Hua L, He Z.

Arch Med Res. 2016 Apr;47(3):186-95. doi: 10.1016/j.arcmed.2016.06.004. Epub 2016 Jul 6.

PMID:
27393961
8.

Molecular Analysis of the HOXA2-Dependent Degradation of RCHY1.

Bridoux L, Deneyer N, Bergiers I, Rezsohazy R.

PLoS One. 2015 Oct 23;10(10):e0141347. doi: 10.1371/journal.pone.0141347. eCollection 2015.

9.

Human Pirh2 is a novel inhibitor of prototype foamy virus replication.

Dong L, Cheng Q, Wang Z, Yuan P, Li Z, Sun Y, Han S, Yin J, Peng B, He X, Liu W.

Viruses. 2015 Apr 2;7(4):1668-84. doi: 10.3390/v7041668.

10.

Aberrant C-terminal domain of polymerase η targets the functional enzyme to the proteosomal degradation pathway.

Ahmed-Seghir S, Pouvelle C, Despras E, Cordonnier A, Sarasin A, Kannouche PL.

DNA Repair (Amst). 2015 May;29:154-65. doi: 10.1016/j.dnarep.2015.02.017. Epub 2015 Feb 26.

PMID:
25766642
11.

Sec8 regulates cytokeratin8 phosphorylation and cell migration by controlling the ERK and p38 MAPK signalling pathways.

Tanaka T, Iino M.

Cell Signal. 2015 Jun;27(6):1110-9. doi: 10.1016/j.cellsig.2015.02.015. Epub 2015 Feb 26.

PMID:
25725287
12.

[TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].

Daks AA, Petukhov AV, Shuvalov OY, Vasilieva EA, Melino G, Barlev NA, Fedorova OA.

Tsitologiia. 2015;57(12):876-9. Russian.

PMID:
26995965
13.

[NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].

Shuvalov OY, Fedorova OA, Petukhov AV, Daks AA, Vasilieva EA, Grigorieva TA, Ivanov GS, Barlev NA.

Tsitologiia. 2015;57(12):847-54. Review. Russian.

PMID:
26995961
14.

Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.

Yan W, Jung YS, Zhang Y, Chen X.

PLoS One. 2014 Aug 12;9(8):e103497. doi: 10.1371/journal.pone.0103497. eCollection 2014.

15.

Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein.

Abou Zeinab R, Wu H, Sergi C, Leng RP.

PLoS One. 2013 Dec 18;8(12):e82803. doi: 10.1371/journal.pone.0082803. eCollection 2013.

16.

The homeodomain transcription factor Hoxa2 interacts with and promotes the proteasomal degradation of the E3 ubiquitin protein ligase RCHY1.

Bergiers I, Bridoux L, Nguyen N, Twizere JC, Rezsöhazy R.

PLoS One. 2013 Nov 7;8(11):e80387. doi: 10.1371/journal.pone.0080387. eCollection 2013.

17.

Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.

Zhao H, Bauzon F, Fu H, Lu Z, Cui J, Nakayama K, Nakayama KI, Locker J, Zhu L.

Cancer Cell. 2013 Nov 11;24(5):645-59. doi: 10.1016/j.ccr.2013.09.021.

18.

Identification of labile Zn sites in drug-target proteins.

Lee YM, Wang YT, Duh Y, Yuan HS, Lim C.

J Am Chem Soc. 2013 Sep 25;135(38):14028-31. doi: 10.1021/ja406300c. Epub 2013 Sep 11.

PMID:
24010488
19.

Cdk9 phosphorylates Pirh2 protein and prevents degradation of p53 protein.

Bagashev A, Fan S, Mukerjee R, Claudio PP, Chabrashvili T, Leng RP, Benchimol S, Sawaya BE.

Cell Cycle. 2013 May 15;12(10):1569-77. doi: 10.4161/cc.24733. Epub 2013 Apr 19.

20.

SCY1-like 1 binding protein 1 (SCYL1-bp1) interacts with p53-induced RING H2 protein (Pirh2) after traumatic brain injury in rats.

Chen J, Zou F, Fu H, Mao H, Gong M, Ni L, Xu X, Shi J, Ke K, Cao M, Zhou F, Shi W.

J Mol Histol. 2013 Jun;44(3):271-83. doi: 10.1007/s10735-013-9488-5. Epub 2013 Mar 12.

PMID:
23479292

Supplemental Content

Loading ...
Support Center